Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Contributed by: GlobeNewswire

Tags

Rheumatoid Arthritis

More Like This

XBiotech Pauses Rheumatology program

GlobeNewswire associated0

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Business Wire logo

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

From left to right: Joana Cunha, Head of Corporate Communication and Compliance; Artur Cavaco Paulo, Co-founder, CEO & CSO; Diana Guimarães, Senior Manager of Product Development & Characterization; Eugénia Nogueira, Co-founder, Operations and HR Director

Solfarcos nears completion of Phase 2a clinical trial for methotrexate nanotechnology treatment of Rheumatoid Arthritis